Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a blood volume monitor for use in hospitals and surgery centers.

Company profile
Ticker
ZYXI
Exchange
Website
CEO
Thomas Sandgaard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Masimo • Natus Medical • LivaNova • Outset Medical • Fonar • Cutera • Inmode ...
Former names
ARIZONA VENTURES INC, CHINA GLOBAL DEVELOPMENT INC, FOX RIVER HOLDINGS INC, IBONZAI COM INC, LIFE MEDICAL TECHNOLOGIES INC /UT/, ZYNEX MEDICAL HOLDINGS INC, ZYNEX MEDICAL HOLDINGS INC
SEC CIK
Corporate docs
Subsidiaries
Zynex Medical, Inc. • Zynex Monitoring Solutions, Inc. • Zynex NeuroDiagnostics, Inc. • Zynex Europe, ApS • Pharmazy, Inc • Kestrel Labs, Inc. ...
IRS number
870403828
ZYXI stock data
Press releases
Zynex Recognized in Top 100 Healthcare Technology Companies of 2022
8 Aug 22
Zynex Ranked in Top 50 Public Companies in Colorado
3 Aug 22
Zynex Announces 2022 Second Quarter Earnings
28 Jul 22
Zynex, Inc. to Announce Second Quarter 2022 Financial Results
20 Jul 22
Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance
11 Jul 22
Calendar
28 Jul 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.88M | 26.88M | 26.88M | 26.88M | 26.88M | 26.88M |
Cash burn (monthly) | 4.12M | 1.31M | (no burn) | (no burn) | 58.67K | (no burn) |
Cash used (since last report) | 5.9M | 1.88M | n/a | n/a | 84K | n/a |
Cash remaining | 20.97M | 25M | n/a | n/a | 26.79M | n/a |
Runway (months of cash) | 5.1 | 19.1 | n/a | n/a | 456.7 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Aug 22 | Daniel J Moorhead | Common Stock | Payment of exercise | Dispose F | No | No | 9.34 | 626 | 5.85K | 47,693 |
5 Aug 22 | Daniel J Moorhead | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 8,012 | 0 | 109,525 |
5 Aug 22 | Anna Lucsok | Common Stock | Payment of exercise | Dispose F | No | No | 9.34 | 97 | 905.98 | 11,601 |
5 Aug 22 | Anna Lucsok | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 3,205 | 0 | 89,708 |
5 Aug 22 | Sandgaard Thomas | Common Stock | Payment of exercise | Dispose F | No | No | 9.34 | 242 | 2.26K | 14,983,205 |
5 Aug 22 | Sandgaard Thomas | Common Stock (Restricted Stock Award) | Grant | Acquire A | No | No | 0 | 8,012 | 0 | 21,777 |
29 Jul 22 | Sandgaard Thomas | Common Stock | Payment of exercise | Dispose F | No | No | 8.58 | 209 | 1.79K | 14,982,795 |
29 Jul 22 | Daniel J Moorhead | Common Stock | Payment of exercise | Dispose F | No | No | 8.58 | 209 | 1.79K | 46,631 |
Institutional ownership, Q1 2022
5.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 29 |
Closed positions | 17 |
Increased positions | 81 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 103.45M |
Total shares | 15.18M |
Total puts | 50.44K |
Total calls | 34.58K |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 3.42M | $21.31M |
Vanguard | 1.41M | $8.82M |
Sandgaard Thomas | 1.3M | $17.02M |
STT State Street | 675.63K | $4.21M |
Allspring Global Investments | 572.19K | $3.56M |
Millennium Management | 532.87K | $3.32M |
Geode Capital Management | 408.73K | $2.55M |
Punch & Associates Investment Management | 394.8K | $2.46M |
GS Goldman Sachs | 360.22K | $2.24M |
Citadel Advisors | 355.93K | $2.22M |
Financial report summary
?Management Discussion
- Net revenue was $36.8 million and $31.0 million for the three months ended June 30, 2022 and 2021, respectively, and $67.8 million and $55.1 million for the six months ended June 30, 2022 and 2021, respectively. Net revenue increased 18% and 23% for the three and six-month periods ended June 30, 2022, respectively. Net income was $3.3 million for the three months ended June 30, 2022 compared with $2.8 million during the same period in 2021. Net income was $4.7 million for the six months ended June 30, 2022 compared with $2.1 million during the same period in 2021. Cash provided by operating activities was $1.6 million during the six months ended June 30, 2022. Working capital was $51.8 million and $59.8 million as of June 30, 2022 and December 31, 2021, respectively.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
announced, competitive, created, flat, fully, funded, HemeOxTM, inflation, instrument, job, NiCOTM, online, publicly, research, shipment, team, trade, utilitzed
Removed:
attributable, September
Financial reports
Current reports
8-K
Zynex Announces 2022 Second Quarter Earnings
28 Jul 22
8-K
Zynex Reports Preliminary Second Quarter 2022 Results and Reiterates Full Year Revenue and EBITDA Guidance
11 Jul 22
8-K
Departure of Directors or Certain Officers
29 Jun 22
8-K
Zynex Announces Change of Auditor
13 Jun 22
8-K
Zynex Announces Additional Share Buyback Program
9 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
19 May 22
8-K
Zynex Announces 2022 First Quarter Earnings
29 Apr 22
8-K
Zynex Announces Share Buyback Program
11 Apr 22
8-K
Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update
8 Apr 22
8-K
Zynex Announces 2021 Fourth Quarter and Full Year Earnings
28 Feb 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Jul 20
424B7
Prospectus with selling stockholder info
16 Jul 20
424B5
Prospectus supplement for primary offering
14 Jul 20
424B7
Prospectus with selling stockholder info
14 Jul 20
424B5
Prospectus supplement for primary offering
29 Oct 19
S-3
Shelf registration
7 Mar 19
8-A12B
Registration of securities on exchange
7 Feb 19
S-8
Registration of securities for employees
5 Sep 17
D
$1.5M in equity / debt
24 Nov 16
Other
EFFECT
Notice of effectiveness
5 Jul 19
UPLOAD
Letter from SEC
1 Jul 19
CORRESP
Correspondence with SEC
30 Jun 19
EFFECT
Notice of effectiveness
13 Mar 19
UPLOAD
Letter from SEC
10 Mar 19
CORRESP
Correspondence with SEC
7 Mar 19
CERT
Certification of approval for exchange listing
11 Feb 19
UPLOAD
Letter from SEC
28 Sep 09
CORRESP
Correspondence with SEC
17 Sep 09
UPLOAD
Letter from SEC
7 Sep 09
Ownership
4
ZYNEX / Thomas Sandgaard ownership change
8 Aug 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
8 Aug 22
4
ZYNEX / Anna Lucsok ownership change
8 Aug 22
4
ZYNEX / Thomas Sandgaard ownership change
29 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
29 Jul 22
4
ZYNEX / Anna Lucsok ownership change
29 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
8 Jul 22
4
ZYNEX / DANIEL J MOORHEAD ownership change
27 Jun 22
4
ZYNEX / Thomas Sandgaard ownership change
27 Jun 22
4
ZYNEX / Anna Lucsok ownership change
27 Jun 22
Patents
Utility
Multiparameter Noninvasive Sepsis Monitor
30 Jun 22
A system for monitoring sepsis comprises one or more sensors that noninvasively monitor a patient to produce sensor data and processing circuitry to: derive, from the sensor data, one or more physiological parameters of the patient that are indicative of a sepsis state of the patient; apply a set of rules to the one or more physiological parameters; determine a sepsis state for the patient based on the set of rules applied to the one or more physiological parameters; and output at least one signal indicative of the sepsis state of the patient.
Utility
Multiparameter Noninvasive Sepsis Monitor
30 Jun 22
A system for monitoring sepsis comprises one or more sensors that noninvasively monitor a patient to produce sensor data and processing circuitry to: derive, from the sensor data, one or more physiological parameters of the patient that are indicative of a sepsis state of the patient; apply a set of rules to the one or more physiological parameters; determine a sepsis state for the patient based on the set of rules applied to the one or more physiological parameters; and output at least one signal indicative of the sepsis state of the patient.
Transcripts
2022 Q2
Earnings call transcript
29 Jul 22
2022 Q1
Earnings call transcript
29 Apr 22
2021 Q4
Earnings call transcript
25 Feb 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
30 Jul 21
2021 Q1
Earnings call transcript
30 Apr 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
28 Apr 20
Reddit threads
MM, showing me they want a specific stock price for a buyout? ZYXI top M&A target imo
23 Jun 22
Market close - Tuesday, June 21 2022 💚🤩
21 Jun 22
Small Cap Bios are primed up - ZYXI + SPPI top picks - XBI ETF ready to run after this next SPY drop. details in comments
6 Jun 22
Very Bullish in Bio right now
27 Jan 22
Daily Discussion Thread - January 5th, 2022
5 Jan 22
Daily Discussion Thread - January 4th, 2022
4 Jan 22
Daily Discussion Thread - January 3rd, 2022
3 Jan 22
Why is Zynex (ZYXI) going sideways?
26 Nov 21
What stock (not discussed here often) do you have the MOST confidence in?
12 Nov 21
Here are 5 stocks moving on abnormal volume today:
3 Nov 21